Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Dec
07
The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis
Nov
22
UCB Submits Response to FDA Complete Response Letter for Bimekizumab
Nov
14
UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients
Sep
26
UCB U.S. Headquarters in Atlanta Awarded Prestigious LEED Gold WELL Platinum Certifications
Sep
22
UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting
Aug
17
UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters
May
23
UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022
May
23
First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022
May
10
UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis
